This study is testing a combination treatment for adults with glioblastoma, a type of brain cancer, that has returned after previous treatment. The treatment involves Laser Interstitial Thermal Therapy (LITT), a procedure that uses a laser guided by MRI to heat and destroy tumor tissue, followed by an oral chemotherapy drug called lomustine (CCNU). Researchers want to see how safe and tolerable this combination treatment is. They are also looking at how long patients live after starting the treatment. You may be able to join if you are an adult with glioblastoma that has come back, and your cancer has been confirmed by a biopsy. This study plans to enroll 20 participants, but its current status is unclear.

Study design

This is a Phase 1 interventional study, meaning it's an early-stage study to test safety. It plans to enroll 20 participants.

What's involved

You would undergo the LITT procedure, followed by one cycle of oral lomustine approximately 7 days later. You will be monitored for side effects and have follow-up appointments based on standard medical care.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for safety for up to 6 weeks after the first dose of lomustine and for tolerability up to 7 days post-LITT. Overall survival will be assessed for up to 2 years after the first dose of lomustine.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.